Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 5/20 | 0.43 |
| ▸ | IDO1 | P14902 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2921477 | 0.81 | CYP1A2 (0.43) | ALDH1A1KMT2ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL2916342 | 0.78 | ALDH1A1 (0.44) | ALDH1A1KMT2AAKR1B1SMN1; SMN2CYP1A2 | |
| SCHEMBL2917193 | 0.77 | KMT2A (0.44) | ALDH1A1KMT2AAKR1B1SMN1; SMN2CYP1A2 | |
| SCHEMBL2594220 | 0.73 | NOS1 (0.44) | TDO2IDO1ALDH1A1KMT2AMAPT | |
| SCHEMBL2144703 | 0.72 | NOS1 (0.53) | TDO2IDO1ALDH1A1MAPTLMNA | |
| SCHEMBL11086324 | 0.72 | KMT2A (0.76) | ALDH1A1KMT2ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL10489810 | 0.72 | AKR1B1 (0.52) | ALDH1A1KMT2AAKR1B1SMN1; SMN2CYP1A2 | |
| SCHEMBL10657842 | 0.72 | SMN1; SMN2 (0.52) | ALDH1A1KMT2AAKR1B1SMN1; SMN2CYP1A2 | |
| SCHEMBL4623724 | 0.71 | ALDH1A1 (0.57) | ALDH1A1KMT2AAKR1B1SMN1; SMN2CYP1A2 | |
| SCHEMBL10489727 | 0.71 | AKR1B1 (0.51) | ALDH1A1KMT2AAKR1B1SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2226315-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2010-09-08 | — | — | EP | disclosed |
| EP-2226315-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2010-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | DSTYK, ABL1, EEF2K | TDO2 2884/4885IDO1 2664/4885ALDH1A1 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.